Asset Details
Do you wish to reserve the book?
An engineered antimicrobial peptide Z-FV7 demonstrates bactericidal efficacy against multidrug-resistant Escherichia coli in a murine model of endometritis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
An engineered antimicrobial peptide Z-FV7 demonstrates bactericidal efficacy against multidrug-resistant Escherichia coli in a murine model of endometritis
Do you wish to request the book?
An engineered antimicrobial peptide Z-FV7 demonstrates bactericidal efficacy against multidrug-resistant Escherichia coli in a murine model of endometritis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
An engineered antimicrobial peptide Z-FV7 demonstrates bactericidal efficacy against multidrug-resistant Escherichia coli in a murine model of endometritis
2025
Overview
Endometritis is a common reproductive disorder in dairy cows, with antibiotics being the primary treatment option. However, the overuse of antibiotics has contributed to the growing problem of antimicrobial resistance. Antimicrobial peptides (AMPs) have been widely studied for their ability to kill bacteria and modulate immune responses. Previous research has focused on modifying natural AMPs extracted from
Zophabas atratus
haemolymph; however, these peptides have displayed limited effectiveness against bacteria. To overcome this limitation, researchers engineered a modified AMP, Z-FV7, by incorporating the sequence of the human-derived AMP LL-37. The resulting peptide demonstrated a favourable safety profile, with a minimum inhibitory concentration (MIC) reduced to 32 μg/mL and improved antibacterial activity against pathogens such as
Staphylococcus aureus
and
Pseudomonas aeruginosa
. Z-FV7 was tested in a bovine uterine epithelial cell model infected with
Escherichia coli
and in a murine model of endometritis. The findings showed that Z-FV7 alleviated clinical symptoms, inhibited the activation of the NF-κB signalling pathway induced by drug-resistant
E. coli
, reduced the expression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), and promoted the expression of tight junction proteins (Claudin-1 and ZO-1). These results indicated that Z-FV7 can help reduce uterine inflammation and provide therapeutic outcomes similar to those of antibiotics during
E. coli
infection. Overall, Z-FV7 holds promise as a potential alternative to antibiotics for treating endometriosis in the future.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Animals
/ Anti-Bacterial Agents - pharmacology
/ Antimicrobial Cationic Peptides - pharmacology
/ Antimicrobial Peptides - pharmacology
/ Bacteria
/ Cattle
/ Drug resistance in microorganisms
/ Drug Resistance, Multiple, Bacterial
/ E coli
/ Escherichia coli - drug effects
/ Escherichia coli Infections - drug therapy
/ Escherichia coli Infections - microbiology
/ Escherichia coli Infections - veterinary
/ Female
/ Medicine
/ Mice
/ minimum inhibitory concentration
/ Multidrug resistant organisms
/ multidrug-resistant bacteria
/ Peptides
/ Proteins
/ Veterinary Medicine/Veterinary Science
/ Virology
